SCHEMBL17344732

SCHEMBL17344732

Cc1cccc(C)c1Nc1ccc(F)cc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
LMNA P02545 1/20 0.58
RAPGEF4 Q8WZA2 6/20 0.52
TSHR P16473 2/20 0.52
CYP1A2 P05177 3/20 0.44
CYP3A4 P08684 3/20 0.44
CYP2D6 P10635 3/20 0.44
CYP2C19 P33261 3/20 0.44
HPGD P15428 2/20 0.44
MAPT P10636 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MAPK1 P28482 1/20 0.44
KDM4E B2RXH2 1/20 0.42
CXCR2 P25025 1/20 0.42
IDO1 P14902 1/20 0.42
SRC P12931 1/20 0.41
CHRNA7 P36544 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4278475 0.89 ALDH1A1 (0.72) ALDH1A1LMNARAPGEF4HPGDCXCR2
SCHEMBL5134264 0.82 RAPGEF4 (0.68) ALDH1A1RAPGEF4HPGDMAPTTDP1
SCHEMBL1921964 0.82 ALDH1A1 (0.64) ALDH1A1LMNARAPGEF4HPGDCXCR2
SCHEMBL4130947 0.81 RAPGEF4 (0.73) RAPGEF4
SCHEMBL24318169 0.80 ALDH1A1 (0.62) ALDH1A1LMNARAPGEF4TSHRCYP1A2
SCHEMBL8014673 0.79 ALDH1A1 (0.61) ALDH1A1RAPGEF4TSHRCYP3A4HPGD
SCHEMBL22202518 0.77 ALDH1A1 (0.58) ALDH1A1RAPGEF4TSHRHPGDTDP1
SCHEMBL15871975 0.77 MAPT (0.46) ALDH1A1LMNATSHRCYP1A2CYP3A4
SCHEMBL24248250 0.76 ALDH1A1 (0.49) ALDH1A1LMNARAPGEF4TSHRMAPT
SCHEMBL2927525 0.75 ALDH1A1 (0.54) ALDH1A1LMNARAPGEF4TSHRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572348-B2 Syntheses of N-heterocyclic carbenes and intermediates therefor UMICORE AG & CO. KG (DE) 2023-02-07 US disclosed
US-20210317088-A9 SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR UMICORE AG & CO. KG (DE) 2021-10-14 US disclosed
US-20200354323-A1 SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR UMICORE AG & CO. KG (DE) 2020-11-12 US disclosed
US-10759763-B2 Syntheses of N-heterocyclic carbenes and intermediates therefor UMICORE AG & CO. KG (DE) 2020-09-01 US disclosed
US-20180186754-A1 SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR UMICORE AG & CO. KG (DE) 2018-07-05 US disclosed
US-9890125-B2 Syntheses of N-heterocyclic carbenes and intermediates therefor UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) 2018-02-13 US disclosed
US-20170152231-A9 SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR UMICORE AG & CO. KG (DE) 2017-06-01 US disclosed
US-20150361049-A1 SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR UNIV ST ANDREWS (GB) 2015-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10759763-B2 Syntheses of N-heterocyclic carbenes and intermediates therefor GRHPR, DDC, NDC1 ALDH1A1 726/4885LMNA 3246/4885RAPGEF4 1736/4885
US-11572348-B2 Syntheses of N-heterocyclic carbenes and intermediates therefor GRHPR, DDC, NDC1 ALDH1A1 726/4885LMNA 3246/4885RAPGEF4 1736/4885
US-20170152231-A9 SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR GRHPR, DDC, WEE2 ALDH1A1 748/4885LMNA 3135/4885RAPGEF4 1722/4885
US-20180186754-A1 SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR GRHPR, DDC, NDC1 ALDH1A1 726/4885LMNA 3246/4885RAPGEF4 1736/4885
US-20210317088-A9 SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR GRHPR, DDC, NDC1 ALDH1A1 726/4885LMNA 3246/4885RAPGEF4 1736/4885
US-20200354323-A1 SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR GRHPR, DDC, NDC1 ALDH1A1 726/4885LMNA 3246/4885RAPGEF4 1736/4885
US-20150361049-A1 SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR GRHPR, DDC, WEE2 ALDH1A1 748/4885LMNA 3135/4885RAPGEF4 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.